AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2654790
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (Ara‐C) at high dose (3.0 g/m2)
Trial: 2654790
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (Ara‐C) at intermediate dose (1.0 g/m2)
Trial: 2654790
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (Ara‐C) at low dose (0.5 g/m2)
Trial: 319122
Drug: Meptazinol (400-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (400-mg capsules)
Trial: 24532471
Drug: Speed-feedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speed-feedback therapy with a bicycle ergometer (once a week for four weeks)
Trial: 17611739
Drug: pergolide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pergolide (0.1 mg)
Trial: 20446946
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel (dual antiplatelet therapy)
Trial: 28554486
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ticagrelor 90 mg once daily
Trial: 28554486
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus ticagrelor 45 mg twice daily
Trial: 28554486
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel 75 mg
Trial: 28554486
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between low-dose ticagrelor groups (90 mg QD and 45 mg BID)
Trial: 28554486
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg QD
Trial: 31930057
Drug: Vortioxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10 mg/day)
Trial: 31990207
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (150 mg/day)
Trial: 19345831
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg) with ethambutol placebo
Trial: 19345831
Drug: Ethambutol (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethambutol (15-20 mg/kg) plus moxifloxacin placebo
Trial: 11296057
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray, 128 microg once daily in the morning and placebo in the evening
Trial: 11296057
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray, 128 microg twice daily
Trial: 11296057
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray, 256 microg once daily in the morning and placebo in the evening
Trial: 9245962
Drug: 10 mM
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM mangafodipir trisodium infusion (MnDPDP) administered at doses of 5 and 10 mumol/kg b.w. by bolus injection (< 1 min) to 5 subjects and by infusion (20 min) to 8 subjects.
Trial: 3788228
Drug: Cimetidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (3 X 200 mg plus 1 X 400 mg daily for one week)
Trial: 3788228
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 X 150 mg daily for one week)
Trial: 31473291
Drug: Drug Holidays
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug Holidays (DH)
Trial: 31473291
Drug: Weight Recovery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight Recovery Treatments (WRT) overall
Trial: 31473291
Drug: CNS Stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS Stimulants
Trial: 18456528
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral ibandronate 150mg
Trial: 11081890
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aprotinin (n = 100)
Trial: 11081890
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aprotinin and epsilon aminocaproic acid (n = 60)
Trial: 3096350
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine supplementation (60 mumol/kg daily) for seven consecutive days
Trial: 3936908
Drug: Oral L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-carnitine supplementation
Trial: 11919725
Drug: rhIL-11, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11, 50 microg/kg subcutaneously daily for up to 21 days
Trial: 11252079
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide supplementation (212 mg.d-1)
Trial: 9260071
Drug: Alcohol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.0 ml/kg)
Trial: 9260071
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (0.1 ml/kg)
Trial: 29621042
Drug: Ocriplasmin 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin 0.125 mg injected once
Trial: 26795064
Drug: Frontline Tri-Act(®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontline Tri-Act(®) topical treatment
Trial: 25008392
Drug: Fulranumab 10
RxNorm normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab 10 mg
Trial: 25008392
Drug: Fulranumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab (1, 3, or 10 mg)
Trial: 19210877
Drug: Iloprost therapy
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost therapy (5-day infusion)
Trial: 16164452
Drug: Low-dose, double-blind,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, double-blind, placebo-controlled food challenge (DBPCFC) with peanut
Trial: 8708947
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) acetate chewing gum (5.0 mg CHX acetate/piece)
Trial: 8708947
Drug: Sorbitol-containing chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol-containing chewing gum (1.0 g sorbitol/piece)
Trial: 8708947
Drug: Xylitol-containing chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol-containing chewing gum (0.8 g xylitol/piece)
Trial: 23888342
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy with physiotherapy (TRT+PT) for 6 months
Trial: 23888342
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy alone (TRT) for 6 months
Trial: 21482968
Drug: Bivalirudin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin monotherapy (n=1800)
Trial: 21482968
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI) (n=1802)
Trial: 17631392
Drug: etoricoxib 30
RxNorm normalized name: Etoricoxib 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 30 mg q.d.
Trial: 17631392
Drug: ibuprofen 2400
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 2400 mg (800 mg t.i.d.)
Trial: 11732707
Drug: Ketamine (noncompetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (noncompetitive NMDA receptor antagonist)
Trial: 10874361
Drug: Nimodipine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (120 mg/day for 28 days)
Trial: 8580704
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of unbound L-tryptophan concentrations using reverse-phase HPLC with fluorescence detection
Trial: 31529159
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adverse events or medication stoppage)
Trial: 29168741
Drug: Tyrosine 100
RxNorm normalized name: tyrosine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine 100 mg/kg
Trial: 29168741
Drug: Tyrosine 200
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine 200 mg/kg
Trial: 29168741
Drug: Tyrosine 150
RxNorm normalized name: TYROSINE 150 ug / PANTOTHENIC ACID 15 mg / METHYLCOBALAMIN 1 mg / CHOLECALCIFEROL 1200 [USP'U] / THIAMINE 1 mg / LEVOMEFOLATE CALCIUM 6 mg / RIBOFLAVIN 5'-PHOSPHATE 3 mg / PYRIDOXAL 5-PHOSPHATE 10 mg / NIACINAMIDE 5 mg / ASCORBIC ACID 85 ug ORAL TABLET [Neuro 110]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine 150 mg/kg (young adults)
Trial: 21942708
Drug: NOMAC/E2 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Trial: 21942708
Drug: LNG/EE (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Trial: 18046544
Drug: Reboxetine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (selective NE reuptake inhibitor)
Trial: 18046544
Drug: Nadolol (peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (peripheral beta-adrenergic antagonist)
Trial: 16141462
Drug: Dual RAAS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAAS blockade (losartan and lisinopril)
Trial: 16141462
Drug: Combined antiproteinuric
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiproteinuric treatment
Trial: 15576063
Drug: Antipanic medication
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipanic medication
Trial: 9349065
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group, n = 20)
Trial: 9349065
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg without adrenaline (plain group, n = 18)
Trial: 9349065
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg with adrenaline 50 micrograms (adrenaline group)
Trial: 9349065
Drug: Pethidine 25
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 25 mg without adrenaline (plain group)
Trial: 3950827
Drug: Fluorescent green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescent green lamps (Sylvania F20T12/G)
Trial: 27392388
Drug: Steroid-eluting ethmoidal
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-eluting ethmoidal stent (SEES)
Trial: 17237853
Drug: Induction 2
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction 2 cycles paclitaxel (175 mg/m2) and carboplatin (AUC 6) followed by concomitant paclitaxel (45 mg/m2) and carboplatin (AUC 2) weekly with radiotherapy (Group A)
Trial: 17237853
Drug: Concomitant carboplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant carboplatin, paclitaxel (same doses as in Group A) and radiotherapy (Group B)
Trial: 17237853
Drug: Only radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only radiotherapy to a total dose of 60 Gy in conventional fractionation (Group C)
Trial: 14616430
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort extract (300 mg, twice daily)
Trial: 14616430
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort extract (300 mg, three times daily)
Trial: 14616430
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive alone (control)
Trial: 10749463
Drug: Ceftriaxone for
RxNorm normalized name: Ceftriaxone for Injection
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone for 4 days (4 injections)
Trial: 8932983
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human interleukin‐6 (rhIL‐6) at doses of 1, 3 or 10 micrograms/kg/day for 7 consecutive days
Trial: 8932983
Drug: cyclophosphamide/G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide/G‐CSF
Trial: 3931145
Drug: Alprazolam 0.5
RxNorm normalized name: alprazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.5 mg b.i.d. for 7 days
Trial: 3931145
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg b.i.d. for 7 days
Trial: 23432142
Drug: Omalizumab 150
RxNorm normalized name: omalizumab 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 150 mg
Trial: 24039365
Drug: PPI (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI (lansoprazole 30 mg/d orally)
Trial: 24039365
Drug: rebamipide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide (300 mg orally, three times a day)
Trial: 21768463
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus tivantinib (ET) - erlotinib (150 mg daily) and tivantinib (360 mg twice daily)
Trial: 21768463
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus placebo (EP) - erlotinib (150 mg daily) and placebo
Trial: 19805683
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose casopitant (150 mg PO on day 1)
Trial: 19805683
Drug: 3-day oral
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day oral casopitant (150 mg PO on day 1 plus 50 mg PO on days 2 to 3)
Trial: 19805683
Drug: 3-day IV/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day IV/oral casopitant (90 mg IV on day 1 plus 50 mg PO on days 2 to 3)
Trial: 17078124
Drug: Recruitment for
RxNorm normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment for treatment trial
Trial: 12477521
Drug: Trial culture
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial culture medium formulation
Trial: 12477521
Drug: Control culture
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control culture medium formulation
Trial: 9717115
Drug: Catheterization using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheterization using a hysteroscopic catheter (3-French diameter tapering to 2 French at the tip)
Trial: 28983556
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg, and verteporfin photodynamic therapy (vPDT)
Trial: 28983556
Drug: Ranibizumab, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab, 0.5 mg, and sham PDT
Trial: 20653397
Drug: Diascorea alata
RxNorm normalized name: Dioscorea alata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diascorea alata (12 mg/sachet, 2 sachets daily for 12 months)
Trial: 9154286
Drug: Latanoprost (0.35,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (0.35, 115, and 350 micrograms/ml) administered topically to both eyes after a baseline day with vehicle (placebo).
Trial: 9154286
Drug: Latanoprost (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (10 times the clinically recommended dose for glaucoma treatment).
Trial: 9154286
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) administered to asthmatic patients on baseline day.
Trial: 8330470
Drug: Torsemide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide (10 mg)
Trial: 26712605
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard lunch followed by normal daily activities)
Trial: 23274402
Drug: Kin Keeper(SM)
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kin Keeper(SM) Cancer Prevention Intervention (treatment group)
Trial: 19686327
Drug: Topical aloe
RxNorm normalized name: Alo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aloe vera (AV)
Trial: 9266098
Drug: Breast Conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast Conserving Therapy (BCT)
Trial: 8318241
Drug: Clonidine infusion
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine infusion
Trial: 31972249
Drug: PF-06700841 30
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 30 mg (n = 14)
Trial: 31972249
Drug: PF-06700841 100
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06700841 100 mg (n = 7)
Trial: 1623705
Drug: Conventional restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional restorative treatment
Trial: 21410557
Drug: Ultraconservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraconservative treatment
Trial: 19597879
Drug: Heparin responsiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin responsiveness in stabilized IE patients
Trial: 19597879
Drug: Heparin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin resistance
Trial: 9218071
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg nocte
Trial: 2979684
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (average dose 10 mg)
Trial: 2979684
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam in lipid emulsion (average dose 18.4 mg)
Trial: 30759357
Drug: Impairment-based manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impairment-based manual therapy
Trial: 28281738
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg daily from 30 min before and up to 3 days after procedure)
Trial: 28281738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous hydration only)
Trial: 23483064
Drug: Cefotaxime sodium
RxNorm normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime sodium 2 g/12 h and intravenous human albumin
Trial: 18981044
Drug: Inhaled L-methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled L-methamphetamine (16 microg)
Trial: 18981044
Drug: Inhaled L-methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled L-methamphetamine (48 microg)
Trial: 12716688
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 50, 100, 200, 400, 600, or 800 micro g daily for 12 weeks
Trial: 12716688
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (estimated adequate dose) 392 micro g daily
Trial: 8636540
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy with transient ischemia (group I)
Trial: 8636540
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy without transient ischemia (group II)
Trial: 1592646
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia (IVA) with pentazocine
Trial: 1972836
Drug: EMLA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 5% cream